publication date: Sep. 21, 2018

As José Baselga clears his desk, MSK forms task force on conflicts; meanwhile, new allegations emerge over center’s role in AI start-up

By Paul Goldberg

José Baselga, who has resigned from his positions as physician-in-chief and chief medical officer at Memorial Sloan Kettering Cancer Center, is winding down his research and clinical activities at that institution, officials said.

After Baselga’s resignation, two publicly traded companies—Bristol-Myers Squibb Co. and Varian Medical Systems Inc.—announced Baselga’s departure from their boards of directors, and MSK has convened a task force physicians, scientists, and external experts to review and update the cancer center’s relevant policies and processes involving conflicts of interest.

The fallout from The New York Times and ProPublica Sept. 8 story about Baselga’s years-long failure to disclose conflicts of interest continued last week as the Times editorial board on Sept. 16 published an editorial about conflicts of interest at the cancer center.

Another Times-ProPublica story published on Sept. 20 questioned MSK’s role in establishing Paige.AI, an artificial intelligence start-up that aims to use the hospital’s pathology archive—consisting of tissue slides from 25 million patients—to develop deep learning algorithms and create a decision support system for pathologists.

“We have requested a correction to The New York Times and ProPublica for statements … Continue reading As José Baselga clears his desk, MSK forms task force on conflicts; Meanwhile, new allegations emerge over center’s role in AI start-up

To access this members-only content, please log in.
If you're not a subscriber why not join today?
If you believe you should be able to view this area but cannot log in, then please contact us and we will try to rectify this issue as soon as possible.
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2018 The Cancer Letter Inc.